BioNet’s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA)

Contributed by: Business Wire

Tags

Health

Other Science

General Health

Research

Science

Pharmaceutical

Biotechnology

Recombinant Pertussis Vaccine

More Like This

Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345

UK MHRA Grants Innovation Passport Designation to ILiAD Biotechnologies BPZE1 Next Generation Intranasal Pertussis Vaccine

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union

Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)

Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)

ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting

Intravacc announces publication of In Vitro alternative to replace animal pyrogen test for vaccines